Volume of Clinical Pathology Laboratory Specimens Increases at Bio-Reference and Sonic Healthcare

Meanwhile, both Quest Diagnostics and LabCorp report second quarter declines in specimen volume Fewer patients visiting physician offices during second quarter 2010 is considered to be one reason why specimen volume declined at clinical pathology laboratory testing giants Quest Diagnostics Incorporated (NYSE: DGX) and Laboratory Corporation of America (NYSE: LH) during that three-month period. For second quarter, LabCorp reported a 2% decline in specimen volume, along with a 4.2% increase in...

Australia’s Pathology Lab Giant Goes Toe-to-Toe with Private Insurers over Higher fees for Pathology Tests

Sonic Healthcare asks for 30% pathology test fee increase from Bupa and MediBank In Australia, reduced funding for pathology testing by government health programs is being blamed as one factor contributing to a contract spat between the nation’s largest clinical laboratory and its major private health insurance companies. Pathologists across the globe will recognize several familiar issues, as Australia’s health institutions struggle to cope with increased utilization of pathology testing and...
;